SYGNIS AG: SYGNIS AG announces management changes

SYGNIS AG / Key word(s): Change of Personnel

05-Jun-2017 / 10:54 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement according to § 17 MAR

—————————————————————————

NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN THE USA, CANADA, JAPAN AND AUSTRALIA

SYGNIS AG announces management changes

Co-CEO Pilar de la Huerta to resign from the management board and to transition to the supervisory board

Madrid, Spain, and Heidelberg, Germany, June 5, 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced changes to the management team. Pilar de la Huerta resigned from her position as member of the management board with effect of the upcoming annual shareholders meeting on July 7, 2017 in order to take on the role of Chief Executive Officer (CEO) in the pharmaceutical industry. With her resignation, Dr. Heikki Lanckriet (previously Co-CEO) will become CEO of SYGNIS AG and will also retain his role as Chief Scientific Officer. Pilar de la Huerta will join the Supervisory Board of SYGNIS AG, subject to the confirmation of the AGM.

**** End of ad hoc announcement ****

For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS AG specializes in the development and commercialization of proprietary technologies and offers a wide range of commercial products addressing key challenges in molecular biology. With the 2016 acquisition of Expedeon Holdings, Ltd. based in the UK, SYGNIS added a complementary proteomics product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. In addition, SYGNIS acquired the profitable U.S.-based life sciences tools company C.B.S. Scientific in December 2016 to further expand its product offering. The products of SYGNIS Group are sold through a direct sales force and several distribution partners in Europe, the U.S. and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the U.S. as well as sales offices in Asia. The company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This document is not a securities prospectus and the information contained herein does not constitute an offer to sell or a solicitation of an offer to purchase any securities of SYGNIS AG in the Federal Republic of Germany nor under any other jurisdiction, in particular not where such kind of offer or solicitation is prohibited or lacks the required permission. Potential investors in securities of SYGNIS AG are asked to familiarize themselves with and to observe the respective restrictions.

The information in this document may not be disseminated outside the Federal Republic of Germany in particular not in the United States, to U.S. Persons (as defined in regulation S of the U.S. Securities Act of 1933) or to publications with a general circulation in the United States with the exception of a such disclosures or announcements outside the Federal Republic of Germany which have to be made under the respective mandatory law. Any person who fails to comply with these restrictions may violate the security laws of certain jurisdictions, in particular of the United States. Securities in SYGNIS AG are not publicly offered outside the Federal Republic of Germany.

Some statements included in this ad hoc announcement, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

Contact:
David Roth
Vorstand/ CFO

SYGNIS AG

Waldhofer Str. 104
69123 Heidelberg, GERMANY

Tel. +49 6221 3540 125
Fax. +49 6221 3540 127


05-Jun-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this